ArticleArthritis and rheumatism2011
Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006.
Article in Arthritis and rheumatism, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03492255 (CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid), which is not on this map. Cited by 112 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid
Who cites it
112 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Immunosuppressive treatment for proliferative lupus nephritis.The Cochrane database of systematic reviews · 2018Pooled it
- American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis.Arthritis care & research · 2012Guideline
- Overcoming barriers to recruitment and retention of African-American women with SLE in behavioural interventions: lessons learnt from the WELL study.Lupus science & medicine · 2020Trial
- Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trial.PLoS medicine · 2019Trial
- Individualized patient decision-aid for immunosuppressive drugs in women with lupus nephritis: study protocol of a randomized, controlled trial.BMC musculoskeletal disorders · 2017Trial
- Advances and unmet needs in the management of proliferative lupus nephritis: evidence, guidelines, and emerging therapies.Kidney research and clinical practice · 2026Article
- Tubulointerstitial inflammation driving interstitial fibrosis and tubular atrophy predicts poor renal outcome in refractory lupus nephritis.Rheumatology (Oxford, England) · 2026Article
- Where, How, and How Much? A Multicenter Cohort Study of the Relationship Across Lupus Decision-Aid Modality, Place of Administration, Interruption and Viewing Completeness, and Patient-Reported Outcomes.Arthritis care & research · 2025Observational
- The Recurrence of Systemic Diseases in Kidney Transplantation.Journal of clinical medicine · 2025Review
- The utility of CXCL13 and circulating CXCR5Frontiers in immunology · 2025Article
- DNase I alleviates renal inflammatory injury in MRL/lpr mice by inhibiting NETs formation.Frontiers in immunology · 2025Article
- The Role of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors in Treating Lupus Nephritis: A Systematic Review.Cureus · 2024Review
- Evaluation and randomised controlled trial of home urinalysis testing in patients with SLE at elevated risk for developing lupus nephritis: a study protocol.Lupus science & medicine · 2024Article
- Observational
- MDIC3: Matrix decomposition to infer cell-cell communication.Patterns (New York, N.Y.) · 2024Article
- Article
- Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis.JCI insight · 2024Article
- Response to belimumab among patients with refractory lupus nephritis: a real-world observational retrospective multicenter study.Clinical rheumatology · 2024Observational
- Article
- Immune podocytes in the immune microenvironment of lupus nephritis (Review).Molecular medicine reports · 2023Review
52 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveThis study was undertaken to investigate whether recent advances in lupus nephritis treatment have led to changes in the incidence of end-stage renal disease (ESRD) secondary to lupus nephritis, or in the characteristics, treatments, and outcomes of patients with lupus nephritis ESRD.
methodsPatients with incident lupus nephritis ESRD (1995-2006) were identified in the US Renal Data System. Trends in sociodemographic and clinical characteristics were assessed. We tested for temporal changes in standardized incidence rates (SIRs) for sociodemographic groups using Poisson regression. Changes in rates of waitlisting for kidney transplant, kidney transplantation, and all-cause mortality were examined using crude and adjusted time-to-event analyses.
resultsWe identified 12,344 incident cases of lupus nephritis ESRD. Mean age at ESRD onset was 41 years; 81.6% of the patients were women and 49.5% were African American. SIRs for lupus nephritis ESRD among those who were ages 5-39 years, African American, or lived in the southeastern US increased significantly from 1995 to 2006. Increases in body mass index and in the prevalence of both diabetes mellitus and hypertension were detected. Mean serum hemoglobin level at ESRD onset increased, while that of serum creatinine decreased over time. More patients received hemodialysis and fewer received peritoneal dialysis. There was a slight increase in the frequency of preemptive kidney transplantation at ESRD onset, but kidney transplantation rates within the first 3 years of ESRD declined. Mortality did not change over the 12 years of study.
conclusionOur findings indicate that the characteristics of patients with lupus nephritis ESRD and initial therapies have changed in recent years. While SIRs rose in younger patients, among African Americans, and in the South, outcomes did not improve in over a decade of evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.